{"id":"W3217304519","doi":"10.1182/blood-2021-149261","title":"A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Blinatumomab; Minimal residual disease; Medicine; Internal medicine; Oncology; Salvage therapy; Hematopoietic stem cell transplantation; Philadelphia chromosome; Transplantation; Maintenance therapy; Donor lymphocyte infusion; Lymphoblastic Leukemia; Leukemia; Immunology; Gastroenterology; Chemotherapy; Chromosomal translocation; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002155221,0.001622266,0.001667072,0.0004912632,0.0004252385,0.001141513,0.001114484,0.001378581,0.003584268],"category_scores_gemma":[0.0008508312,0.0006261494,0.0009658916,0.0005044045,0.0008995489,0.0006925754,0.0003957195,0.00390666,0.001031146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007470898,"about_ca_system_score_gemma":0.001663037,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008540978,"about_ca_topic_score_gemma":0.001443908,"domain_scores_codex":[0.9995105,0.00027842,0.00002062915,0.00006537818,0.00004526351,0.00007982086],"domain_scores_gemma":[0.9992796,0.0001279759,0.0001162235,0.00007231397,0.00005581306,0.0003480348],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6550878,0.1620548,0.004120997,0.001738523,0.001330019,0.0004594427,0.0005067883,0.002826049,0.07192371,0.0004561243,0.004071409,0.09542435],"study_design_scores_gemma":[0.5868188,0.4011712,0.004142346,0.00004536235,0.0002844778,0.0002592511,0.0000543988,0.0007764811,0.003824683,0.0001619432,0.002444661,0.00001643536],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887706,0.00262881,0.001060427,0.0005899709,0.0001693823,0.00421431,0.0009561586,0.0001427208,0.001467715],"genre_scores_gemma":[0.9833361,0.00291357,0.00262058,0.0009481713,0.0001713341,0.004733486,0.002521259,0.0000487875,0.002706647],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003584268,"threshold_uncertainty_score":0.01199055,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03104877772732599,"score_gpt":0.3233730235897129,"score_spread":0.2923242458623869,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}